EZH2 and leukemia: In this context, inhibiting EZH2 in cell lines, primary cells and xenograft mouse models to de-condense the H3K27me3-marked chromatin of AML cells was shown to improve accessibility to chromatin and suppress leukemia through chemotherapy-induced DNA damage as well as apoptosis (Porazzi et al., 2022).